SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market
Holding SABS?
Track your performance easily

SAB Biotherapeutics (SABS) Financial Statements

73 Followers

SAB Biotherapeutics Financial Overview

SAB Biotherapeutics's market cap is currently ―. The company's EPS TTM is $-6.166; its P/E ratio is -0.45; SAB Biotherapeutics is scheduled to report earnings on November 12, 2024, and the estimated EPS forecast is $-1.10. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 263.14K$ 944.58K$ 1.27M$ 85.52K$ 581.10K
Gross Profit$ 263.14K$ 944.58K$ 1.27M$ 85.52K$ 581.10K
EBIT$ -7.24M$ -4.95M$ -5.03M$ -6.81M$ -7.32M
EBITDA$ -6.10M$ -3.05M$ -4.05M$ -5.91M$ -6.40M
Net Income Common Stockholders$ -7.34M$ -5.03M$ -5.10M$ -6.88M$ 8.61M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 37.33M$ 44.06M$ 2.43M$ 7.77M$ 13.06M
Total Assets$ 61.89M$ 71.37M$ 28.34M$ 35.44M$ 42.67M
Total Debt$ 5.34M$ 5.45M$ 4.65M$ 4.90M$ 5.46M
Net Debt$ -31.98M$ -38.61M$ 2.23M$ -2.87M$ -7.60M
Total Liabilities$ 15.77M$ 18.55M$ 13.08M$ 15.73M$ 18.27M
Stockholders Equity$ 46.12M$ 52.82M$ 15.26M$ 19.72M$ 24.40M
Cash Flow-
Free Cash Flow$ -7.77M$ -10.88M$ -5.21M$ -4.92M$ -1.63M
Operating Cash Flow$ -7.72M$ -10.75M$ -5.17M$ -4.90M$ -1.61M
Investing Cash Flow$ 11.22M$ -31.36M$ -40.86K$ -22.68K$ -21.30K
Financing Cash Flow$ -321.04K$ -394.42K$ -140.31K$ -363.79K$ -359.79K
Currency in USD

SAB Biotherapeutics Earnings and Revenue History

SAB Biotherapeutics Debt to Assets

SAB Biotherapeutics Cash Flow

SAB Biotherapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis